ArticlePloS one2012
Sphingosine 1-phosphate modulates antigen capture by murine Langerhans cells via the S1P2 receptor subtype.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- Plasma Levels of the Bioactive Sphingolipid Metabolite S1P in Adult Cystic Fibrosis Patients: Potential Target for Immunonutrition?Nutrients · 2020Trial
- Review
- Pathogenic sphingosine 1-phosphate pathway in psoriasis: a critical review of its pathogenic significance and potential as a therapeutic target.Lipids in health and disease · 2023Review
- Sphingosine 1-Phosphate as Essential Signaling Molecule in Inflammatory Skin Diseases.International journal of molecular sciences · 2023Review
- Review
- Uncovering the 'sphinx' of sphingosine 1-phosphate signalling: from cellular events to organ morphogenesis.Biological reviews of the Cambridge Philosophical Society · 2022Review
- Atopic dermatitis: an expanding therapeutic pipeline for a complex disease.Nature reviews. Drug discovery · 2022Review
- Ceramides in Skin Health and Disease: An Update.American journal of clinical dermatology · 2021Review
- The Importance of Metabolism for Immune Homeostasis in Allergic Diseases.Frontiers in immunology · 2021Review
- Topical Application of S1PBiomolecules & therapeutics · 2020Article
- Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases.International journal of molecular sciences · 2019Review
- Mast cells and sphingosine-1-phosphate underlie prelesional remodeling in a mouse model of eczema.Allergy · 2018Article
- Nuclear Translocation of SGPP-1 and Decrease of SGPL-1 Activity Contribute to Sphingolipid Rheostat Regulation of Inflammatory Dendritic Cells.Mediators of inflammation · 2017Article
- Sphingosine-1-phosphate and other lipid mediators generated by mast cells as critical players in allergy and mast cell function.European journal of pharmacology · 2016Review
- Activation-Induced Cell Death of Dendritic Cells Is Dependent on Sphingosine Kinase 1.Frontiers in pharmacology · 2016Article
- Sphingosine-1-Phosphate Receptor-2 Antagonists: Therapeutic Potential and Potential Risks.Frontiers in pharmacology · 2016Review
- Endothelial sphingosine kinase/SPNS2 axis is critical for vessel-like formation by human mesoangioblasts.Journal of molecular medicine (Berlin, Germany) · 2015Article
- Enhanced sphingosine-1-phosphate receptor 2 expression underlies female CNS autoimmunity susceptibility.The Journal of clinical investigation · 2014Article
- Involvement of sphingosine 1-phosphate in palmitate-induced insulin resistance of hepatocytes via the S1P2 receptor subtype.Diabetologia · 2014Article
- Pseudomonas-derived ceramidase induces production of inflammatory mediators from human keratinocytes via sphingosine-1-phosphate.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendritic cells (DCs) play a pivotal role in the development of cutaneous contact hypersensitivity (CHS) and atopic dermatitis as they capture and process antigen and present it to T lymphocytes in the lymphoid organs. Recently, it has been indicated that a topical application of the sphingolipid sphingosine 1-phosphate (S1P) prevents the inflammatory response in CHS, but the molecular mechanism is not fully elucidated. Here we indicate that treatment of mice with S1P is connected with an impaired antigen uptake by Langerhans cells (LCs), the initial step of CHS. Most of the known actions of S1P are mediated by a family of five specific G protein-coupled receptors. Our results indicate that S1P inhibits macropinocytosis of the murine LC line XS52 via S1P(2) receptor stimulation followed by a reduced phosphatidylinositol 3-kinase (PI3K) activity. As down-regulation of S1P(2) not only diminished S1P-mediated action but also enhanced the basal activity of LCs on antigen capture, an autocrine action of S1P has been assumed. Actually, S1P is continuously produced by LCs and secreted via the ATP binding cassette transporter ABCC1 to the extracellular environment. Consequently, inhibition of ABCC1, which decreased extracellular S1P levels, markedly increased the antigen uptake by LCs. Moreover, stimulation of sphingosine kinase activity, the crucial enzyme for S1P formation, is connected not only with enhanced S1P levels but also with diminished antigen capture. These results indicate that S1P is essential in LC homeostasis and influences skin immunity. This is of importance as previous reports suggested an alteration of S1P levels in atopic skin lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.